Compare L3Harris Technologies Inc (LHX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? L3Harris Technologies Inc trades at $285.3 (market cap $53.26B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: L3Harris Technologies Inc is far larger — about 29.4× Recursion Pharmaceuticals Inc's market cap, and L3Harris Technologies Inc pays a 1.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LHX | RXRX | |
|---|---|---|
Market Cap | $53.26B | $1.81B |
Sector | Industrials | Health |
52-Week High | $378.48 | $6.79 |
52-Week Low | $270.21 | $2.84 |
Enterprise Value | $63.71B | $1.33B |
Dividend Yield | 1.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $285.18, down 1.57% today, with strong fundamental performance including three consecutive quarterly EPS beats and record $42 billion backlog. The company shows improving profitability with net margin expanding to 8.11% in 2026 projections. Recent defense contract wins and successful missile tests highlight operational momentum, though technical indicators show bearish pressure with price below key resistance levels.
LHX presents a compelling investment case with strong defense sector positioning, consistent earnings outperformance, and 72.7% analyst buy ratings targeting $319.33. Key risks include defense budget volatility and execution challenges in scaling production. The stock offers 12% upside to consensus target with dividend yield support, though near-term technical weakness requires monitoring.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
